S

    Surrozen Inc (SRZN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $22.02
    -0.40 (-1.78%)

    Market Cap: $263.51M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(10/20)
    Avg Surprise
    -41.80%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.32
    Range$-1.33 - $-1.30
    3 analysts
    EPS RevisionsNo revisions (7d)
    0
    2
    30d
    EPS Estimate Drift
    90d ago$-1.29+1.9%
    60d ago$-1.29+1.9%
    30d ago$-1.29+1.9%
    7d ago$-1.33-0.8%
    Current$-1.32
    Revenue Consensus
    $373800
    Range$0 - $1M
    5 analysts
    Dec 31, 2026
    EPS Consensus$-5.84
    Range$-5.84 - $-5.84
    1 analysts
    Revenue Consensus
    $6M
    Range$5M - $7M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-5.84---
    Sep 26EST
    		-$-1.32---
    Jun 26
    		$-0.41N/A+69.40%Beat+64.0%
    Mar 26
    		$-4.63$-0.72-543.06%Miss-158.5%
    Dec 25
    		$-9.62$-1.24-678.79%Miss-5.8%
    Sep 25
    		$-3.60$-1.17-207.69%Miss-718.2%
    Jun 25
    		$-1.14$-1.23+7.32%Beat+85.7%
    Mar 25
    		$7.92$-1.09+826.61%Beat+286.8%
    Dec 24
    		$-9.09$-2.70-236.67%Miss-106.1%
    Sep 24
    		$-0.44N/A+84.12%Beat+91.4%
    Jun 24
    		$-7.99$-2.79-186.38%Miss-71.8%
    Mar 24
    		$-4.24$-4.25+0.24%Beat+41.1%
    Dec 23
    		$-4.41$-3.00-47.00%Miss-14600.0%
    Sep 23
    		$-5.10$-4.20-21.43%Miss+10.5%
    Jun 23
    		$-4.65$-6.00+22.50%Beat+22.5%
    Mar 23
    		$-7.20$-5.42-32.84%Miss-108.7%
    Dec 22
    		$-0.03N/A+93.02%Beat+95.0%
    Sep 22
    		$-5.70$-6.43+11.35%Beat+25.5%
    Jun 22
    		$-6.00$-6.90+13.04%Beat-1478.9%
    Mar 22
    		$-3.45N/A+57.41%Beat-1012.9%
    Dec 21
    		$-0.60$-0.44-36.36%Miss-
    Sep 21
    		$-7.65$-5.85-30.77%Miss-
    Jun 21
    		$-0.38N/AN/ABeat-
    Mar 21
    		$-0.31N/AN/ABeat-
    Dec 20
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-1.21EV/EBITDA0.71x
    Price/FCF-7.34xFCF Yield-13.62%
    Profitability
    Profit Margin0.00%Operating Margin-207.40%
    ROE-62.80%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio12.14xQuick Ratio12.14x
    Trading Statistics
    Beta0.56Avg Volume223.47K
    52-Week High$35.0052-Week Low$11.25

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$23.50
    SMA 20$23.60
    SMA 50$23.07
    SMA 200$23.88
    EMA 10$23.24
    EMA 20$23.24
    EMA 50$23.46
    EMA 200$22.58

    MACD

    Line: 0.06Signal: 0.24Hist: -0.18

    ADX

    ADX: 13.5+DI: 17.7-DI: 19.2

    Aroon & PSAR

    Aroon Up36.0
    Aroon Down8.0
    PSAR$26.78

    Bollinger Bands

    Upper Band$25.79
    Lower Band$21.41
    %B Position1857%(Upper)
    Band Width0.14

    RSI (14-Day)

    Neutral
    42.2

    Momentum Oscillators

    Stoch %K18.5
    Stoch %D24.9
    Williams %R-86.9
    ROC (10d)-7.4%
    Momentum-1.76
    CCI (20d)-133.7
    MFI (14d)38.6

    Volatility Measures

    ATR (14d)$1.66(7.6%)
    StdDev (20d)1.10
    Hist Vol75.4%(High)

    Volume Flow

    VWAP$22.03
    OBV4.8M
    AD Line849.1K
    CMF (20d)-0.193

    Volume Metrics

    Avg Vol (20d)223.1K
    Vol Ratio1.2x
    VWMA (20d)$23.53

    Pivot Points

    R3$25.00
    R2$24.37
    R1$23.40
    Pivot Point$22.77
    S1$21.80
    S2$21.17
    S3$20.20

    Advanced Oscillators

    TSI1.85
    Ultimate Osc37.8
    KST62.65

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$5.00M$5.00M$528,000$983,000$983,000$983,000$655,000$10.00M$0$0$0$0
    Cost of Revenue$0$0$45,000$0$0$0$322,000$0$0$0N/A$0
    Gross Profit$5.00M$5.00M$528,000$983,000$983,000$983,000$655,000$10.00M$0$0N/A$0
    Operating Expenses$15.37M$15.46M$13.17M$11.87M$10.00M$10.53M$9.25M$8.77M$9.05M$9.13M$9.72M$11.19M
    R&D$8.48M$9.33M$8.99M$7.77M$6.04M$6.56M$5.35M$5.20M$5.33M$5.25M$6.09M$6.11M
    SG&A$6.89M$6.13M$4.18M$4.09M$3.96M$3.98M$3.90M$3.57M$3.71M$3.88M$3.59M$3.57M
    Operating Income$-10,370,000$-10,456,000$-12,639,000$-10,885,000$-9,017,000$-9,551,000$-8,592,000$1.23M$-9,049,000$-9,130,000$-9,724,000$-11,189,000
    Interest Income$938,000$912,000$788,000$911,000$1.02M$296,000$387,000$431,000$490,000$385,000$509,000$661,000
    Interest Expense$0$40.19M$18.06M$60.76M$0$34.88M$20.52M$2.67M$0$0$0$0
    Income Before Tax$10.93M$-50,650,000$-30,697,000$-71,643,000$8.23M$-44,427,000$-29,115,000$-1,434,000$-4,864,000$-8,830,000$-9,311,000$-10,445,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$50.18M$-127,505,000$-183,159,000$-71,643,000$39.75M$-26,970,000$-48,436,000$-1,434,000$-4,864,000$-8,830,000$-8,913,000$-10,445,000
    EBITDA$10.04M$-51,497,000$-31,440,000$-72,493,000$7.34M$-44,429,000$-29,180,000$-1,523,000$-4,968,000$-8,466,000$-9,413,000$-10,831,000
    EBIT$9.99M$-51,562,000$-31,485,000$-72,554,000$7.20M$-44,723,000$-29,502,000$-1,865,000$-5,354,000$-9,215,000$-9,820,000$-11,106,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SRZN

    News

    William Blair initiates Surrozen stock with Outperform rating

    William Blair has initiated coverage of Surrozen Inc. (NASDAQ:SRZN) with an Outperform rating and a fair value estimate of $51 per share. The biotechnology company, which focuses on developing multispecific antibodies for retinal diseases, has seen a 109% return over the past year. This positive outlook is supported by recent reiterations of a buy rating from H.C. Wainwright, highlighting confidence in Surrozen's clinical pipeline, including its lead antibody SZN-8141 for diabetic macular edema.

    Investing.com•8/21/26•
    Bullish

    William Blair initiates Surrozen stock with Outperform rating

    William Blair has initiated coverage on Surrozen Inc. (NASDAQ:SRZN) with an Outperform rating and a $51 fair value estimate, citing the company's progress in developing multispecific antibodies for retinal diseases. This positive outlook is supported by H.C. Wainwright's reiterated buy rating and a $44 price target, highlighting Surrozen's lead antibody SZN-8141, which is expected to enter clinical trials for diabetic macular edema. These developments indicate strong analyst confidence in Surrozen's clinical pipeline and future prospects.

    Investing.com•8/20/26•
    Bullish

    William Blair initiates Surrozen stock with Outperform rating By Investing.com

    William Blair has initiated coverage on Surrozen Inc. (NASDAQ:SRZN) with an Outperform rating and a fair value estimate of $51 per share, citing its promising pipeline of multispecific antibodies for retinal diseases. Despite the stock trading at $24.01 with a 109% return over the past year, InvestingPro analysis suggests it may be overvalued relative to its fair value, though analysts maintain a strong buy consensus. This initiation follows H.C. Wainwright's reiterated buy rating for Surrozen, emphasizing confidence in the company's clinical developments, including its lead candidate SZN-8141 for diabetic macular edema.

    Investing.com UK•8/20/26•
    Bullish

    William Blair Initiates Surrozen at Outperform

    William Blair has initiated coverage of Surrozen, Inc. with an "Outperform" rating. This news was published on August 20, 2026, at 06:55 am EDT. Surrozen is a biotechnology company focused on developing drug candidates to modulate the Wnt pathway for conditions like retinal diseases and Fuchs' Endothelial Corneal Dystrophy.

    marketscreener.com•8/20/26•
    Bullish

    Braidwell group reports 3.9% Surrozen (SRZN) holding in amended 13G filing

    Braidwell LP and affiliated reporting persons have disclosed a beneficial ownership of 460,753 shares of Surrozen, Inc. common stock, representing approximately 3.9% of the class. This holding includes 390,753 directly owned shares and 70,000 shares acquirable through warrants within 60 days. The filing, an amended 13G, indicates shared voting and dispositive power for all reported shares and notes the ownership is 5 percent or less of the class.

    Stock Titan•8/14/26•
    Neutral

    Frequently Asked Questions About SRZN

    Does SRZN pay dividends?
    Surrozen Inc (SRZN) does not currently pay a regular dividend.
    What is SRZN's market cap?
    Surrozen Inc (SRZN) has a market capitalization of $263.51M with a current stock price of $22.02.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In